BioMarin Pharmaceutical (BMRN) 2026 stock analysis: orphan-drug moat, Voxzogo achondroplasia growth and competition, the Amicus acquisition, Roctavian's commercial miss, pricing risk, and the quarterly metrics that matter.
ADMA Biologics stock outlook for 2026, covering the ASCENIV and BIVIGAM specialty immunoglobulin franchise, vertically integrated plasma collection, pediatric label expansion, competitive pressure from Grifols and CSL, and the concentration and regulatory risks investors should weigh before buying ADMA shares.
Pharmicell (005690) stock outlook for 2026. A deep, qualitative look at how mPEG and nucleoside fine-chemical cash flow funds the Cellgram stem-cell pipeline, Korea's first approved autologous stem-cell drug legacy, valuation, and the real risks.
HLB Life Science (067630) 2026 stock outlook. An honest, qualitative breakdown of the HLB Group rivoceranib anticancer FDA re-filing narrative, what it means to be a value-chain proxy rather than the lead applicant, the group cross-shareholding and dilution risk, and why this is a binary event-driven biotech, not a fundamentals story.
Nibec (138610) 2026 stock outlook. A deep, qualitative look at the KOSDAQ peptide platform company's cell-penetrating drug-delivery and tissue-regeneration technology, its cash-generating bone-graft and dental biomaterials, the out-licensing upside, and the clinical and cash-burn risks foreign investors should weigh.
GI Innovation 2026 stock outlook. A qualitative deep dive into the dual-fusion protein platform, the GI-101, GI-301 and GI-108 pipeline, the Yuhan out-licensing partnership, milestone-recognition lumpiness, binary clinical risk, cash runway and dilution.
OliX Pharmaceuticals (KOSDAQ 226950) 2026 stock outlook. A qualitative deep dive into its asymmetric siRNA (asiRNA) and GalNAc-conjugated RNAi platform, the hypertrophic scar, wet AMD, hair loss and metabolic pipeline, the out-licensing model, and the binary clinical and cash-runway risks foreign investors must weigh.
Oscotec (039200) 2026 stock analysis: how the lazertinib royalty stream through Genosco cushions the downside, why the SYK inhibitor cevidoplenib drives the upside, and how a US investor should size a speculative clinical-stage Korean biotech with KRW exposure.
Genexine (095700) stock outlook for 2026. A deep look at the hyFc long-acting protein platform, the IL-7 immuno-oncology and rare-disease pipeline, the NeoImmuneTech link, R&D losses and dilution risk, and how it stacks up against Hanmi and Alteogen.
Exelixis (EXEL) 2026 stock analysis: the Cabometyx (cabozantinib) franchise cash flow, Ipsen and Takeda royalties, the zanzalintinib next-gen pipeline, patent-cliff and generic-entry timing, and a buyback-first capital allocation strategy explained.
Halozyme (HALO) stock outlook 2026. A deep qualitative read on the ENHANZE subcutaneous drug-delivery royalty model, Darzalex SC concentration, partner dependence, the late-2020s patent-expiry cliff, buyback-driven capital allocation, and the metrics that actually matter.
Caregen (KOSDAQ 214370) 2026 stock outlook. A deep qualitative look at its peptide IP moat, ultra-high margins and cash generation, cosmeceutical skin boosters and mesotherapy, the Reverse blood-sugar peptide health-food line, filler and hair pipeline, and the concentration and FX risks facing a royalty and export-heavy model.
ToolGen (KOSDAQ 199800) 2026 stock outlook. A deep qualitative look at its CRISPR gene-editing foundational patent IP, the contested Cas9 priority disputes, the licensing and milestone royalty model, agri and therapeutic pipelines, and how a foreign investor should size and manage a high-risk Korean biotech option.
Bioneer (KOSDAQ 064550) 2026 stock outlook. A deep qualitative look at the post-COVID normalization of its PCR molecular-diagnostics cycle, in-house oligonucleotide synthesis moat, the long-dated SAMiRNA self-assembled siRNA drug-delivery platform (hair loss and anti-fibrosis pipeline), steady probiotics consumer cash flow, peer comparison versus Seegene, and how to value the diagnostics segment separately from the drug platform.
Charles River Laboratories (CRL) 2026 stock analysis: the three-pillar preclinical CRO model spanning research models, DSA safety assessment, and CDMO manufacturing, the razor-and-consumable repeat-demand engine, leverage to a recovering biotech funding cycle, NHP primate supply and regulatory risk, and a peer comparison against IQVIA, ICON, Medpace, and Inotiv.
MEDP (Medpace Holdings) 2026 stock outlook. A qualitative deep dive into the founder-led, single-integrated full-service CRO built for small and mid-cap biotech, its high margins and book-to-bill engine, and why net new business awards and backlog swing with the biotech funding cycle, benchmarked against IQVIA, ICON, and Charles River.
Voronoi (KOSDAQ 310210) 2026 stock outlook. A deep look at its brain-penetrant precision kinase oncology platform, the out-licensing royalty and milestone business model, the clinical-binary, cash-burn and dilution risks, Korean biotech peer comparison, and what foreign investors should know about KRW currency exposure.
Peptron (087010) 2026 stock analysis: the SmartDepot long-acting drug delivery platform, converting weekly GLP-1 into monthly dosing via microspheres, big-pharma option value, sustained-release prostate cancer pipeline, and the binary clinical, dilution, and cash-runway risks that make this a speculative bet.
INSM (Insmed) stock outlook for 2026. A qualitative deep dive into the Arikayce revenue base for NTM lung disease, the brensocatib bronchiectasis catalyst, the TPIP pulmonary hypertension pipeline, and the commercialization-transition and cash-burn risks that define this late-stage biotech.
NTRA (Natera) 2026 stock outlook. A qualitative deep dive into Signatera tumor-informed MRD testing and Panorama prenatal (NIPT) recurring revenue, test volume and ASP dynamics, insurance coverage as the key lever, Guardant and Exact Sciences competition, and the path to profitability.
ST Pharm (237690) 2026 stock outlook. A deep qualitative look at its world-leading oligonucleotide CDMO position, RNA-drug demand from inclisiran, siRNA and GLP-1-adjacent pipelines, Dong-A Socio group backing, and the capacity-expansion cycle that drives the shares.
HanAll Biopharma (009420) 2026 stock outlook. A deep qualitative look at the batoclimab FcRn autoimmune franchise, the Immunovant and Harbour BioMed out-licensing royalty and milestone structure, the tanfanercept dry-eye pipeline, Daewoong group synergy, clinical catalysts, and the risks a US investor should weigh.
ABL Bio (KOSDAQ 298380) 2026 stock analysis: the Grabody-B blood-brain-barrier shuttle platform, the Sanofi Parkinson's licensing deal, 4-1BB bispecific immuno-oncology, ADC pipeline, milestone-and-royalty revenue, and the clinical and cash-burn risks.
Sarepta Therapeutics (SRPT) Stock Outlook 2026 covering the ELEVIDYS DMD gene therapy, the 2025 patient-death safety events and FDA scrutiny that crushed the stock, the exon-skipping revenue base, RNA and gene-therapy pipeline, binary biotech risk, peer comparison and what global investors should weigh on tax, currency and dilution.